Hereditary Angioedema clinical trials

Explore recruiting hereditary angioedema clinical trials.

Recruiting hereditary angioedema studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hereditary Angioedema trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktail

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema - ALPHA-ORBIT

Spain, Germany, Bulgaria, France, Hungary, Austria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Poland, Italy, Hungary, France, Austria, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Belgium, Poland, Italy, Czechia, Hungary, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

France, Hungary, Italy, Slovakia, Germany, Ireland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hereditary Angioedema trials by city

Hereditary Angioedema in Toronto Hereditary Angioedema in Vancouver Hereditary Angioedema in Montreal Hereditary Angioedema in Calgary Hereditary Angioedema in Edmonton Hereditary Angioedema in Ottawa Hereditary Angioedema in Winnipeg Hereditary Angioedema in Quebec City Hereditary Angioedema in Hamilton Hereditary Angioedema in Kitchener Hereditary Angioedema in London Hereditary Angioedema in Halifax Hereditary Angioedema in New York Hereditary Angioedema in Los Angeles Hereditary Angioedema in Chicago Hereditary Angioedema in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease